Direct Targeting
KRAS G12C inhibitors
KRAS mutations
non-small cell lung cancer
phenotypic changes
resistance mechanisms
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
04 Mar 2022
04 Mar 2022
Historique:
received:
21
11
2021
revised:
15
02
2022
accepted:
17
02
2022
entrez:
10
3
2022
pubmed:
11
3
2022
medline:
11
3
2022
Statut:
epublish
Résumé
KRAS is the most frequently mutated oncogene in non-small cell lung cancers (NSCLC), with a frequency of around 30%, and encoding a GTPAse that cycles between active form (GTP-bound) to inactive form (GDP-bound). The
Identifiants
pubmed: 35267628
pii: cancers14051321
doi: 10.3390/cancers14051321
pmc: PMC8909472
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
Cancer Discov. 2018 Jul;8(7):822-835
pubmed: 29773717
Nat Rev Drug Discov. 2016 Nov;15(11):771-785
pubmed: 27469033
Lung Cancer. 2010 Sep;69(3):272-8
pubmed: 20022659
Nat Rev Cancer. 2007 Mar;7(3):169-81
pubmed: 17318210
Ther Adv Med Oncol. 2017 Sep;9(9):589-597
pubmed: 29081842
N Engl J Med. 2018 May 31;378(22):2078-2092
pubmed: 29658856
Cancer Discov. 2021 Aug;11(8):1874-1876
pubmed: 34344756
Cancer Discov. 2021 Aug;11(8):1913-1922
pubmed: 33824136
N Engl J Med. 2009 Sep 3;361(10):947-57
pubmed: 19692680
Clin Cancer Res. 2020 Apr 1;26(7):1538-1540
pubmed: 32001483
Clin Cancer Res. 2017 Jun 15;23(12):3012-3024
pubmed: 28039262
J Thorac Oncol. 2019 Jun;14(6):1095-1101
pubmed: 30738221
Proc Natl Acad Sci U S A. 2019 Oct 29;116(44):22122-22131
pubmed: 31611389
Br J Cancer. 2005 Jan 17;92(1):131-9
pubmed: 15597105
Cancer Treat Res Commun. 2020;24:100200
pubmed: 32750661
J Thorac Dis. 2020 Sep;12(9):5086-5095
pubmed: 33145085
J Thorac Oncol. 2022 Mar;17(3):399-410
pubmed: 34740862
N Engl J Med. 2020 Sep 24;383(13):1207-1217
pubmed: 32955176
N Engl J Med. 2021 Jun 24;384(25):2371-2381
pubmed: 34096690
Nature. 2020 Jan;577(7790):421-425
pubmed: 31915379
Cancer Cell. 2019 Apr 15;35(4):559-572.e7
pubmed: 30905761
Nat Rev Cancer. 2019 Sep;19(9):495-509
pubmed: 31406302
Cancer Discov. 2021 Jun;11(6):1345-1352
pubmed: 33820777
Lancet. 2016 Apr 2;387(10026):1415-1426
pubmed: 26777916
Eur J Cancer. 2020 Sep;137:57-68
pubmed: 32745965
Proc Natl Acad Sci U S A. 2019 Feb 12;116(7):2551-2560
pubmed: 30683722
Clin Cancer Res. 2018 Jan 15;24(2):334-340
pubmed: 29089357
J Thorac Oncol. 2021 Aug;16(8):1321-1332
pubmed: 33971321
N Engl J Med. 2020 Jan 2;382(1):41-50
pubmed: 31751012
Nature. 2019 Nov;575(7781):217-223
pubmed: 31666701
Ann Oncol. 2021 Sep;32(9):1101-1110
pubmed: 34089836
Clin Lung Cancer. 2013 May;14(3):205-14
pubmed: 23122493
Clin Cancer Res. 2020 Nov 15;26(22):5962-5973
pubmed: 32900796
N Engl J Med. 2021 Jan 14;384(2):185-187
pubmed: 33497555
Cancer Discov. 2020 Jan;10(1):54-71
pubmed: 31658955
Cancers (Basel). 2019 Oct 09;11(10):
pubmed: 31600989
Hum Genomics. 2017 Jun 21;11(1):13
pubmed: 28637487
Cell. 2020 Nov 12;183(4):850-859
pubmed: 33065029
Ann Oncol. 2018 Oct 1;29(Suppl 4):iv192-iv237
pubmed: 30285222
Mol Cancer. 2021 Oct 4;20(1):128
pubmed: 34607583
Cancer Discov. 2020 Aug;10(8):1129-1139
pubmed: 32430388
Clin Cancer Res. 2021 Oct 15;27(20):5697-5707
pubmed: 34365406
J Thorac Oncol. 2013 May;8(5):530-42
pubmed: 23524403
Nat Med. 2020 Feb;26(2):169-170
pubmed: 32020086
Clin Cancer Res. 2020 Apr 1;26(7):1633-1643
pubmed: 31776128
Nature. 2021 Nov;599(7886):679-683
pubmed: 34759319
N Engl J Med. 2021 Jun 24;384(25):2382-2393
pubmed: 34161704
J Thorac Oncol. 2019 Apr;14(4):606-616
pubmed: 30605727
Nat Rev Drug Discov. 2020 Aug;19(8):533-552
pubmed: 32528145
Nature. 2013 Nov 28;503(7477):548-51
pubmed: 24256730
Clin Cancer Res. 2012 Nov 15;18(22):6169-77
pubmed: 23014527
J Thorac Oncol. 2015 Sep;10(9):1240-1242
pubmed: 26291007
PLoS One. 2009 Oct 14;4(10):e7464
pubmed: 19826477
J Thorac Oncol. 2015 Sep;10(9):1243-1260
pubmed: 26291008
Lung Cancer. 2021 Oct;160:152-165
pubmed: 34417059